Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study

Figure 3

(a) Evolution of SBP by type of antihypertensive treatment (ITT), (b) evolution of DBP by age cohort between V1 and V3 (ITT population, 𝑁=5603), (c) evolution of SBP by menopausal status (ITT population; 𝑛=2772), and (d) evolution of DBP by menopausal status (ITT population; 𝑛=2772).

(a)

(b)

(c)

(d)